nach oben

Erschienen in:

01.03.2006

Immunological Basis for IgE Hyper-Production in Enfuvirtide-Treated HIV- Positive Patients

verfasst von: Samuele E. Burastero, Clara Paolucci, Daniela Breda, Armando Soldarini, Fernanda Dorigatti, Elisa Soprana, Hamid Hasson, Priscilla Biswas, Adriano Lazzarin, Antonella Castagna

Erschienen in: Journal of Clinical Immunology | Ausgabe 2/2006

Einloggen, um Zugang zu erhalten

Abstract

We previously reported that enfuvirtide (ENF) treatment is accompanied by a selective increase of serum IgE. We asked whether ENF had intrinsic capability to direct B-lymphocytes to switch to IgE and/or if it could drive CD4 T cells to a Th2 phenotype. ENF was added in vitro: (a) to B-lymphocytes stimulated with IgE-switch inducing stimuli; (b) to peripheral blood mononuclear cells. Total IgE production by B cells and IL4 and IFN-γ production by CD4 T lymphocytes were evaluated, respectively. ENF had no measurable effect on the IgE production by B-lymphocytes. In contrast, it sharply increased the IL4 to IFN-γ (a correlate of the Th2 phenotype) when added in vitro to T cells from healthy donors or from single ENF-treated patients. The hyper-IgE production in ENF-treated patients is associated with the in vitro induction of a type-2 phenotype in CD4 T cells.

Moore JP, Doms RW: The entry of entry inhibitors: A fusion of science and medicine. Proc Natl Acad Sci USA 100:10598–10602, 2003CrossRefPubMed

Castagna A, Biswas P, Beretta A, Lazzarin A: From discovery of biological mechanisms to drug development: the appealing history of drug inhibitors. Drugs 65: 879–904, 2005

Cervia JS, Smith MA: Enfuvirtide (T-20): A novel human immunodeficiency virus type 1 fusion inhibitor. Clin Infect Dis 37:1102–1106, 2003CrossRefPubMed

Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D: Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3:215–225, 2004CrossRefPubMed

Asboe D: Enfuvirtide: Antiretroviral class 4, drug 1. HIV Clin Trials 5:1–6, 2004CrossRefPubMed

Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Jr., Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175–2185, 2003CrossRefPubMed

Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348:2186–2195, 2003CrossRefPubMed

Myers SA, Selim A, McDaniel M: A prospective clinical and histological examination of infection sites with the fusion inhibitor enfuvirtide (ENF). Fortythird Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago (USA), 2003: Abstract H-2015

Fung HB, Guo Y: Enfuvirtide: A fusion inhibitor for the treatment of HIV infection. Clin Ther 26:352–378, 2004CrossRefPubMed

10.

Hardy H, Skolnik PR: Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 24:198–211, 2004CrossRefPubMed

11.

Ball RA, Kinchelow T: Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol 49:826–831, 2003CrossRefPubMed

12.

Hasson H, Danise A, Carini E, Bigoloni A, Galli A, Bonora S, Biswas P, Vecchi A, Lazzarin A, Castagna A: Increase in serum IgE levels during enfuvirtide treatment in multidrug-resistant HIV-1 infected patients. XV International AIDS Conference, July 11–16. Bangkok, Thailand, 2004:Abstract TuPeB4560

13.

Jabara HH, Fu SM, Geha RS, Vercelli D: CD40 and IgE: Synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med 172:1861–1864, 1990CrossRefPubMed

14.

Jabara HH, Schneider LC, Shapira SK, Alfieri C, Moody CT, Kieff E, Geha RS, Vercelli D: Induction of germ-line and mature C epsilon transcripts in human B cells stimulated with rIL-4 and EBV. J Immunol 145:3468–3473, 1990PubMed

15.

Kohl C, Debelic M: In vitro screening for inhalant allergy with multi SX 1 RAST (Phadiatop). Allergy 46:245–250, 1991PubMedCrossRef

16.

Casali P, Burastero SE, Nakamura M, Inghirami G, Notkins AL: Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 236:77–81, 1987PubMedCrossRef

17.

Burastero SE, Lo Pinto G, Goletti D, Cutolo M, Burlando L, Falagiani P: Rheumatoid arthritis with monoclonal IgE rheumatoid factor. J Rheumatol 20:489–494, 1993PubMed

18.

Zhang L, Carruthers CD, He T, Huang Y, Cao Y, Wang G, Hahn B, Ho DD: HIV type 1 subtypes, coreceptor usage, and CCR5 polymorphism. AIDS Res Hum Retrovir 13:1357–1366, 1997PubMedCrossRef

19.

Vercelli D: Novel insights into class switch recombination. Curr Opin Allergy Clin Immunol 2:147–151, 2002CrossRefPubMed

20.

He B, Raab-Traub N, Casali P, Cerutti A: EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 171:5215–5224, 2003PubMed

21.

Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H, Life P, Talabot D, Flores-Romo L, Thompson J, et al.: Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 365:340–343, 1993CrossRefPubMed

22.

Burd PR, Thompson WC, Max EE, Mills FC: Activated mast cells produce interleukin 13. J Exp Med 181:1373–1380, 1995CrossRefPubMed

23.

Braun MC, Wang JM, Lahey E, Rabin RL, Kelsall BL: Activation of the formyl peptide receptor by the HIV-derived peptide T-20 suppresses interleukin-12 p70 production by human monocytes. Blood 97:3531–3536, 2001CrossRefPubMed

24.

Su SB, Gong WH, Gao JL, Shen WP, Grimm MC, Deng X, Murphy PM, Oppenheim JJ, Wang JM: T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor. Blood 93:3885–3892, 1999PubMed

25.

Deng X, Ueda H, Su SB, Gong W, Dunlop NM, Gao JL, Murphy PM, Wang JM: A synthetic peptide derived from human immunodeficiency virus type 1 gp120 downregulates the expression and function of chemokine receptors CCR5 and CXCR4 in monocytes by activating the 7-transmembrane G-protein-coupled receptor FPRL1/LXA4R. Blood 94:1165–1173, 1999PubMed

26.

Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4:1302–1307, 1998CrossRefPubMed

27.

Romagnani S, Maggi E: Th1 versus Th2 responses in AIDS. Curr Opin Immunol 6:616–622, 1994CrossRefPubMed

28.

Romagnani S, Del Prete G, Manetti R, Ravina A, Annunziato F, De Carli M, Mazzetti M, Piccinni MP, D’Elios MM, Parronchi P, et al.: Role of TH1/TH2 cytokines in HIV infection. Immunol Rev 140:73–92, 1994PubMedCrossRef

29.

Maggi E, Mazzetti M, Ravina A, Annunziato F, de Carli M, Piccinni MP, Manetti R, Carbonari M, Pesce AM, del Prete G, et al.: Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells. Science 265:244–248, 1994PubMedCrossRef

30.

Israel-Biet D, Labrousse F, Tourani JM, Sors H, Andrieu JM, Even P: Elevation of IgE in HIV-infected subjects: A marker of poor prognosis. J Allergy Clin Immunol 89:68–75, 1992CrossRefPubMed

31.

Vigano A, Principi N, Crupi L, Onorato J, Vincenzo ZG, Salvaggio A: Elevation of IgE in HIV-infected children and its correlation with the progression of disease. J Allergy Clin Immunol 95:627–632, 1995PubMedCrossRef

32.

Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, Dolan MJ, Hendrix CW, Wolf SF, Shearer GM: Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 262:1721–1724, 1993PubMedCrossRef

33.

Graziosi C, Pantaleo G, Gantt KR, Fortin JP, Demarest JF, Cohen OJ, Sekaly RP, Fauci AS: Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 265:248–252, 1994PubMedCrossRef

34.

Wild C, Dubay JW, Greenwell T, Baird T, Jr., Oas TG, McDanal C, Hunter E, Matthews T: Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci USA 91:12676–12680, 1994PubMedCrossRef

35.

Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 91:9770–9774, 1994PubMedCrossRef

36.

Lawless MK, Barney S, Guthrie KI, Bucy TB, Petteway SR Jr., Merutka G: HIV-1 membrane fusion mechanism: Structural studies of the interactions between biologically-active peptides from gp41. Biochemistry 35:13697–13708, 1996CrossRefPubMed

Titel: Immunological Basis for IgE Hyper-Production in Enfuvirtide-Treated HIV- Positive Patients
verfasst von: Samuele E. Burastero
Clara Paolucci
Daniela Breda
Armando Soldarini
Fernanda Dorigatti
Elisa Soprana
Hamid Hasson
Priscilla Biswas
Adriano Lazzarin
Antonella Castagna
Publikationsdatum: 01.03.2006
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 2/2006
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-006-9005-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Immunological Basis for IgE Hyper-Production in Enfuvirtide-Treated HIV- Positive Patients

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2006

Increased Apoptosis of CD20+ IgA+ B Cells is the Basis for IgA Deficiency: The Molecular Mechanism for Correction In Vitro by IL-10 and CD40L

Increased Spontaneous Ex Vivo Apoptosis and Subset Alterations in Peripheral Blood T Cells from Patients with Multiple Sclerosis

Two Mutations of the C7 Gene, c.1424G > A and c.281-1G > T, in Two Korean Families

Self-Reactive CD4+ T Cells and B Cells in the Blood in Health and Autoimmune Disease: Increased Frequency of Thyroglobulin-Reactive Cells in Graves’ Disease

Aberrant Expression of CC and CXC Chemokines and Their Receptors in Patients with Asthma

Interferon-Gamma Responses to Candida Recover Slowly or Remain Low in Immunodeficient HIV Patients Responding to ART

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin